192 related articles for article (PubMed ID: 38652455)
21. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
22. Taking a BiTE out of the CAR T space race.
Patel A; Oluwole O; Savani B; Dholaria B
Br J Haematol; 2021 Dec; 195(5):689-697. PubMed ID: 34131894
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
24. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
25. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
26. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
27. Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies.
Kowalski A; Lykon J; Diamond B; Coffey DG; Kaddoura M; Maura F; Hoffman JE; Kazandjian D; Landgren O
Blood Cancer Discov; 2024 Mar; 5(2):90-94. PubMed ID: 38175152
[TBL] [Abstract][Full Text] [Related]
28. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy.
Johnson PC; Neckermann I; Sadrzadeh H; Newcomb R; El-Jawahri AR; Frigault MJ
Transplant Cell Ther; 2024 May; 30(5):490-499. PubMed ID: 38412928
[TBL] [Abstract][Full Text] [Related]
30. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
31. Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity.
Schmidts A; Wehrli M; Maus MV
Annu Rev Med; 2021 Jan; 72():365-382. PubMed ID: 32776808
[TBL] [Abstract][Full Text] [Related]
32. Reactions Related to CAR-T Cell Therapy.
Miao L; Zhang Z; Ren Z; Li Y
Front Immunol; 2021; 12():663201. PubMed ID: 33995389
[TBL] [Abstract][Full Text] [Related]
33. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract][Full Text] [Related]
34. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
[TBL] [Abstract][Full Text] [Related]
35. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
36. [Practical aspects of the application of CAR T cells and management of their toxicities].
Bücklein V; Blumenberg V; Subklewe M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
[TBL] [Abstract][Full Text] [Related]
38. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
39. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy.
Tedesco VE; Mohan C
J Immunol; 2021 Apr; 206(7):1561-1568. PubMed ID: 33692146
[TBL] [Abstract][Full Text] [Related]
40. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]